Education
About Us
Working with TipRanks
Follow Us
Pyxis Oncology, Inc. (PYXS)
:PYXS
PYXS Stock Chart & Stats
$4.39
-$0.10(-5.75%)
At close: 4:00 PM EST
$4.39
-$0.10(-5.75%)
Day’s Range― - ―
52-Week Range$0.83 - $5.55
Previous CloseN/A
Volume258.73K
Average Volume (3M)682.96K
Market Cap
$273.34M
Enterprise Value$80.22M
Total Cash (Recent Filing)$77.73M
Total Debt (Recent Filing)$19.07M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Mar 25, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding62,264,214
10 Day Avg. Volume535,924
30 Day Avg. Volume682,961
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.76
Price to Sales (P/S)5.65
P/FCF Ratio-1.57
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue28.45
Enterprise Value/Gross Profit28.45
Enterprise Value/Ebitda-0.98
Forecast
1Y Price Target
$7.20Price Target Upside64.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.3
Revenue Forecast (FY)$2.81M
Bulls Say, Bears Say
Bulls Say
Clinical Development AccelerationPreliminary data from one of the cohorts is now expected earlier than previously guided, indicating a potential acceleration in clinical development.
Collaborative PartnershipsPyxis Oncology has a clinical trial collaboration agreement with Merck for the combination with Keytruda.
Financial StabilityThe company reported having approximately $77.7M in cash and equivalents, which is believed to be sufficient to fund operations into the second half of 2026.
Bears Say
Clinical Results UncertaintyInitial Phase I data of Micvo in head-and-neck cancer results as difficult to differentiate with only modest activity in other areas.
Financial Health ConcernsThe company has approximately one year of cash left based on the current annualized cash burn.
Revenue ChallengesPyxis Oncology reported no revenues for the quarter and a net loss that was slightly higher than consensus estimates.
Pyxis Oncology News
PYXS FAQ
What was Pyxis Oncology, Inc.’s price range in the past 12 months?
Pyxis Oncology, Inc. lowest stock price was $0.83 and its highest was $5.55 in the past 12 months.
What is Pyxis Oncology, Inc.’s market cap?
Pyxis Oncology, Inc.’s market cap is $273.34M.
When is Pyxis Oncology, Inc.’s upcoming earnings report date?
Pyxis Oncology, Inc.’s upcoming earnings report date is Mar 25, 2026 which is in 111 days.
How were Pyxis Oncology, Inc.’s earnings last quarter?
Pyxis Oncology, Inc. released its earnings results on Nov 03, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.334 by -$0.016.
Is Pyxis Oncology, Inc. overvalued?
According to Wall Street analysts Pyxis Oncology, Inc.’s price is currently Undervalued.
Does Pyxis Oncology, Inc. pay dividends?
Pyxis Oncology, Inc. does not currently pay dividends.
What is Pyxis Oncology, Inc.’s EPS estimate?
Pyxis Oncology, Inc.’s EPS estimate is -0.33.
How many shares outstanding does Pyxis Oncology, Inc. have?
Pyxis Oncology, Inc. has 62,264,214 shares outstanding.
What happened to Pyxis Oncology, Inc.’s price movement after its last earnings report?
Pyxis Oncology, Inc. reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.334. Following the earnings report the stock price went up 7.022%.
Which hedge fund is a major shareholder of Pyxis Oncology, Inc.?
Currently, no hedge funds are holding shares in PYXS
Pyxis Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.20 (64.01% Upside)
$7.20 (64.01% Upside)
Blogger Sentiment
Bullish
PYXS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.8%
Last 30 Days ▲ 11.2%
Last 30 Days ▲ 11.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.40%
12-Months-Change
Fundamentals
Return on Equity
-87.28%
Trailing 12-Months
Asset Growth
-45.93%
Trailing 12-Months
Company Description
Pyxis Oncology, Inc.
Pyxis Oncology, Inc. (PYXS) is a biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs) and immuno-oncology therapeutics for the treatment of cancer. The company operates within the healthcare sector, primarily targeting oncology as its core field. Pyxis Oncology aims to address unmet medical needs by leveraging its proprietary platforms to discover and develop innovative therapies that improve patient outcomes.
PYXS Stock 12 Month Forecast
Average Price Target
$7.20
▲(64.01% Upside)
Technical Analysis
Nkarta
―
Greenwich LifeSciences
―
Elicio Therapeutics
―
Biomea Fusion
―
Nuvectis Pharma
―
Ownership Overview
10.26%
Insiders
4.33% Mutual Funds
24.44% Other Institutional Investors
57.27% Public Companies and
Individual Investors